JAMP-FINASTERIDE TABLET

Šalis: Kanada

kalba: anglų

Šaltinis: Health Canada

Veiklioji medžiaga:

FINASTERIDE

Prieinama:

JAMP PHARMA CORPORATION

ATC kodas:

G04CB01

INN (Tarptautinis Pavadinimas):

FINASTERIDE

Dozė:

5MG

Vaisto forma:

TABLET

Sudėtis:

FINASTERIDE 5MG

Vartojimo būdas:

ORAL

Vienetai pakuotėje:

30

Recepto tipas:

Prescription

Gydymo sritis:

5 ALFA REDUCTASE INHIBITORS

Produkto santrauka:

Active ingredient group (AIG) number: 0124110001; AHFS:

Autorizacija statusas:

APPROVED

Leidimo data:

2014-10-10

Prekės savybės

_JAMP-Finasteride_
_(finasteride) _
_ _
_ _
_ _
_Page 1 of 31_
PRODUCT MONOGRAPH
PR
JAMP-FINASTERIDE
Finasteride Tablets, USP
Film-coated Tablets 5 mg
Type II 5α-reductase inhibitor
JAMP PHARMA CORPORATION
1310 rue Nobel
Boucherville, Quebec
J4B 5H3, Canada
DATE OF REVISION:
April 5, 2023 SUBMISSION CONTROL NO.: 268915
_JAMP-Finasteride_
_(finasteride) _
_ _
_ _
_ _
_Page 2 of 31_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.......................................................... 3
SUMMARY PRODUCT INFORMATION
........................................................................
3
INDICATIONS AND CLINICAL USE
..............................................................................
3
CONTRAINDICATIONS
...................................................................................................
4
WARNINGS AND PRECAUTIONS
..................................................................................
4
ADVERSE REACTIONS
...................................................................................................
6
DRUG
INTERACTIONS
.....................................................................................................
9
DOSAGE AND ADMINISTRATION
..............................................................................
10
OVERDOSAGE
................................................................................................................
12
ACTION AND CLINICAL PHARMACOLOGY
............................................................ 12
STORAGE AND STABILITY
..........................................................................................
13
SPECIAL HANDLING INSTRUCTIONS
.......................................................................
13
DOSAGE FORMS, COMPOSITION AND PACKAGING
............................................. 13
PART II: SCIENTIFIC INFORMATION
................................................................................
14
PHARMACEUTICAL INFORMATION
..........................................................................